Get the Stockscreener App
28.07
1.09%
-0.31
Gh Research Plc stock is traded at $28.07, with a volume of 177.77K.
It is down -1.09% in the last 24 hours and up +4.43% over the past month.
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.
See More
Previous Close:
$28.38
Open:
$28.5
24h Volume:
177.77K
Relative Volume:
0.70
Market Cap:
$1.93B
Revenue:
-
Net Income/Loss:
$-48.26M
P/E Ratio:
-35.54
EPS:
-0.7899
Net Cash Flow:
$-45.04M
1W Performance:
+2.90%
1M Performance:
+4.43%
6M Performance:
+79.25%
1Y Performance:
+95.47%
1-Day Range:
$27.86
$28.85
1-Week Range:
$26.32
$29.05
52-Week Range:
$11.32
$31.00
Gh Research Plc Stock (GHRS) Company Profile
Compare GHRS vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GHRS
Gh Research Plc
|
28.07 | 1.90B | 0 | -48.26M | -45.04M | -0.7899 |
VRTX
Vertex Pharmaceuticals Inc
|
477.10 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
762.63 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
853.82 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
187.53 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
316.01 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Gh Research Plc Stock (GHRS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-13-25 | Initiated | Needham | Buy |
| Jun-04-25 | Resumed | Cantor Fitzgerald | Overweight |
| Mar-13-25 | Initiated | Guggenheim | Buy |
| Mar-07-25 | Initiated | RBC Capital Mkts | Outperform |
| Feb-13-25 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-16-22 | Initiated | H.C. Wainwright | Buy |
| Jun-16-22 | Initiated | ROTH Capital | Buy |
View All
Gh Research Plc Stock (GHRS) Latest News
GH Research PLC (GHRS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
GHRS|GH Research PLC|Price:27.830|Chg%:+0.550 - TradingKey
GHRS Initiated Coverage by Wells Fargo -- Price Target Announced at $44 - GuruFocus
GH Research PLC (GHRS) Institutional Confidence - TradingKey
GH Research PLC (GHRS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
GH Research PLC (GHRS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
GH Research PLC (GHRS) Valuation: PE, PB & Fair Value Analysis - TradingKey
GHRS|GH Research PLC|Price:27.280|Chg%:-0.350 - TradingKey
GH Research PLC (GHRS) Cash Flow - TradingKey
GH Research PLC Revenue Breakdown – NASDAQ:GHRS - TradingView
TradingKey - TradingKey
GH Research PLC (GHRS) Balance Sheet - TradingKey
GH Research PLC (GHRS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
GHRS: GH Research PLC Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
A Depression Drug Just Cleared a Key Hurdle Early, and the Market for New Mental Health Treatments Keeps Widening - marketscreener.com
GH Research PLC (1KA.DU) Analyst insights, Price targets and Recommendations - Yahoo Finance UK
Why is GH Research stock trading higher on Thursday? - MSN
Price-Driven Insight from (GHRS) for Rule-Based Strategy - Stock Traders Daily
Samsara Stock And 2 Founder Led Software Picks With Real Revenue Growth - Sahm
Eli Lilly Drops $3.8 Billion on AtaiBeckley, Sending Psychedelic Stocks Soaring - finance.biggo.com
Big Pharma Just Paid Up to $3.8 Billion for Psychedelic Medicine, and the Rest of the Sector Is Being Repriced in Real Time - Finansavisen
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Sahm
AtaiBeckley surges after report Lilly poised to buy psychedelic drug developer - Sahm
GHR Research PLC stock hits 52-week high at $30.20 - Investing.com
GHR Research PLC stock hits 52-week high at $30.20 By Investing.com - Investing.com South Africa
GH Research : GHRS - 24/7 Wall St.
Why Is GH Research Stock Trading Higher on Thursday? - Benzinga
Why is GH Research stock surging today? By Investing.com - Investing.com Nigeria
GH Research PLC (GHRS:UW): Stock Price, Quote and News - BNN Bloomberg
Eli Lilly Enters Psychedelic Drug Race With Up to $3.8 Billion AtaiBeckley Deal - finance.biggo.com
Why Psychedelic stocks are surging today - Yahoo Finance UK
GH Research (GHRS) In Focus As FDA Psychedelic Shift Raises The Question Of Value - Sahm
GH Research gains on optimism surrounding potential Eli Lilly-Atai deal (GHRS) - Yahoo Finance
Why is GH Research stock surging today? - Investing.com
GH Research stock jumps on Eli Lilly-Atai acquisition talks By Investing.com - Investing.com Nigeria
GH Research Surges 3.08% as Bullish Momentum Builds Above Key SupportCollar Trade - dars.gov.et
GH Research (GHRS) Declines Over 4% as Stock Tests Key Support LevelsGamma Squeeze - dars.gov.et
A3CUAZ Forecast — Price Target — Prediction for 2027 - TradingView
GH Research (GHRS) price target increased by 18.94% to 40.04 - MSN
GH Research (GHRS) Gains Ground: Bouncing Toward Key Resistance at $28.23Resistance Breakout Stocks - dars.gov.et
Price to sales forward of GH Research PLC – NASDAQ:GHRS - TradingView
Price to book forward of GH Research PLC – NASDAQ:GHRS - TradingView
GHRSGH Research PLC Options - Finviz
GH RESEARCH PLC (GHRS) Stock Chart - ChartMill
AtaiBeckley Stock Outlook Depends on Key Pipeline Catalysts in 2026 - TradingView
Is AtaiBeckley Stock Worth Buying After Its Stronger Rally in 2026? - TradingView
GH Research Plc Actuals & Estimates (FWB:1KA) - TradingView
Pre-Market Movement | GH Research Shares Surge to 52-Week High - 富途牛牛
GHRS Forecast — Price Target — Prediction for 2027 - TradingView
GHRS Stock Price and Chart — NASDAQ:GHRS - TradingView
(GHRS) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Gh Research Plc Stock (GHRS) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.44%
0.02%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):